Technological developments in embolization products & procedures and growing inclination toward minimally invasive processes drive the growth of the global.
Interim 12-week analysis from the ongoing Phase 2a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel), receives International Continence